Literature DB >> 6193808

Primary structure of papain-solubilized human histocompatibility antigen HLA-B40 (-Bw60). An outline of alloantigenic determinants.

J López de Castro, R Bragado, D M Strong, J L Strominger.   

Abstract

The primary structure of papain-solubilized human histocompatibility antigen HLA-B40 (-Bw60) has been determined. Its comparison with that of the cross-reactive HLA-B7 antigen allows for the first time a direct sequence comparison between two HLA-B locus products and an outline of the location of their alloantigenic sites. Overall sequence homology between HLA-B40 and HLA-B7 is 93%. Of 19 detected differences, 18 are located in the two amino-terminal domains (residues 1-182). Half of them are clustered in two short segments spanning residues 63-74 and 147-156, respectively, which suggests that they may encompass major sites of their alloantigenic determinants. The first of these segments is highly polymorphic in HLA and H-2 molecules. It is proposed that it may belong to a hypervariable region of class I histocompatibility antigens. The remaining substitutions are scattered through the N-terminal portions of the two external domains. Thus, in addition to the above-mentioned segments, other positions may contribute significantly to the antigenic polymorphism of these molecules.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193808     DOI: 10.1021/bi00285a036

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

1.  DNA sequence of HLA-A11: remarkable homology with HLA-A3 allows identification of residues involved in epitopes recognized by antibodies and T cells.

Authors:  E P Cowan; M L Jelachich; W E Biddison; J E Coligan
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

2.  A transposable epitope of HLA-B7, B40 molecules.

Authors:  J P Ways; D A Lawlor; A M Wan; P Parham
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  Expression of an HLA-Bw6-related specificity by the HLA-Cw3 molecule.

Authors:  C Layet; T Delovitch; P Ferrier; D H Caillol; B R Jordan; F A Lemonnier
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

4.  Isolation, expression, and the primary structure of HLA-Cw1 and HLA-Cw2 genes: evolutionary aspects.

Authors:  D Güssow; R S Rein; I Meijer; W de Hoog; G H Seemann; F M Hochstenbach; H L Ploegh
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

5.  The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two genetic mechanisms.

Authors:  T Ooba; H Hayashi; S Karaki; M Tanabe; K Kano; M Takiguchi
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

6.  Nomenclature for factors of the HLA system, 1989. The WHO Nomenclature Committee.

Authors: 
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

7.  Transfection of murine LMTK- cells with purified HLA class I genes. VII. Association of allele- and locus-specific serological reactivities with respectively the first and second domains of the HLA-B7 molecule.

Authors:  R Sodoyer; B Kahn-Perles; T Strachan; J Sire; M J Santoni; C Layet; P Ferrier; B R Jordan; F A Lemonnier
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

8.  A new public antigen shared by all HLA-A locus products except HLA-A23, -A24, -A32, and -A25 is probably influenced by the amino acid residue at position 79 in the alpha 1 domain.

Authors:  L P de Waal; C van der Meer; A R van der Horst; F H van der Velde
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

9.  Complete sequence of HLA-B27 cDNA identified through the characterization of structural markers unique to the HLA-A, -B, and -C allelic series.

Authors:  H Szöts; G Riethmüller; E Weiss; T Meo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

10.  DNA sequence of the coding region of the HLA-B44 gene.

Authors:  A H Kottmann; G H Seemann; H D Guessow; M H Roos
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.